Company profile for Alumis

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Alumis is dedicated to transforming the lives of patients grappling with immune diseases through a precision-oriented approach. Our objective is to enhance patient lives substantially by replacing broad immunosuppression with targeted therapies. Our existence is centered around addressing the specific needs of these patients. We are at the forefront of pioneering a precision approach that utilizes insights derived from powerfu...
Alumis is dedicated to transforming the lives of patients grappling with immune diseases through a precision-oriented approach. Our objective is to enhance patient lives substantially by replacing broad immunosuppression with targeted therapies. Our existence is centered around addressing the specific needs of these patients. We are at the forefront of pioneering a precision approach that utilizes insights derived from powerful data analytics to select the right target, molecule, indication, patient, and endpoint, ultimately optimizing outcomes for patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
611 Gateway Blvd, Suite 820, South San Francisco, California 94080
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/03/02/3247361/0/en/Alumis-to-Present-at-the-Leerink-Partners-Global-Healthcare-Conference.html

GLOBENEWSWIRE
02 Mar 2026

https://www.globenewswire.com/news-release/2026/02/05/3232969/0/en/Alumis-to-Participate-in-Upcoming-February-Investor-Conferences.html

GLOBENEWSWIRE
05 Feb 2026

https://www.globenewswire.com/news-release/2026/01/09/3216342/0/en/Alumis-Announces-Closing-of-Upsized-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html

GLOBENEWSWIRE
09 Jan 2026

https://www.indianpharmapost.com/clinical-trials/alumis-reports-breakthrough-phase-3-results-for-oral-psoriasis-therapy-18803

INDPHARMAPOST
08 Jan 2026

https://www.globenewswire.com/news-release/2026/01/06/3214139/0/en/Alumis-Announces-Proposed-Public-Offering-of-Common-Stock.html

GLOBENEWSWIRE
06 Jan 2026

https://www.globenewswire.com/news-release/2026/01/06/3213465/0/en/Alumis-Envudeucitinib-Delivers-Leading-Skin-Clearance-Among-Next-Generation-Oral-Plaque-Psoriasis-Therapies-in-Phase-3-Program.html

GLOBENEWSWIRE
06 Jan 2026

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty